ACCESSIBILITY

24/7

Headlines

15:36

Israel to invest over $30M in groundbreaking lab for bio-devices and biochips development

15:32

"People worry AI will replace them, but those who master it will thrive"

15:24

War games of a different kind: Games developed in this war have a higher purpose

15:11

"AI will not replace game developers - it will make their lives easier"

Buzz

Most popular

Daily

Weekly

Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?

Windward acquired for $270M by FTV Capital, doubling its IPO valuation

$41B in exits: Why Israeli cyber startups are a global powerhouse

Kaltura CEO: "Just like a missile hit our office, a missile hit us with the IPO"

Coralogix acquires Aporia in $50M deal to boost AI system transparency

More news

Teva

20 stories about Teva

JPMorgan Downgrades Teva’s Stock to Underweight

13.11.17|Amarelle Wenkert

Christopher Schott, managing director at JPMorgan, said that the decision to downgrade is based on the challenges facing Teva’s generic drug unit

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich

Mylan is currently the highest valued company on the TASE at $18.5 billion

Fitch Downgrades Teva to Junk Rating

07.11.17|Yaniv Rahimi

The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt

There May Be a Silver Lining to Teva’s Woes

06.11.17|Eli Shimony

Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer

Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer

For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer

Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer

Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer

The stem-cell therapy company diluted Teva’s shares through a new offering in August

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer

According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Previous Articles More Articles